Pipeline Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update BioPharma DiveImmunovant shares climbed on results an analyst deemed compelling in tough-to-treat arthritis.Immunology & InflammationRead full story pharminent May 20, 2026 (Last updated: May 20, 2026) BioPharma Dive Immunovant shares climbed on results an analyst deemed compelling in tough-to-treat arthritis. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pazdur declines to announce candidacy for vacated FDA commissioner roleNext: Remepy’s hybrid Parkinson’s therapy poised for phase 3 Related Stories Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
